FGEN FibroGen Inc

55.05
-0.25  -0%
Previous Close 55.30
Open 56.00
Price To book 17.04
Market Cap 3919297191
Shares 71,195,226
Volume 369,738
Short Ratio 2.96
Av. Daily Volume 1,083,726

SEC filingsSee all SEC filings

  1. 8-K - Current report 171141793
  2. 8-K - Current report 171092595
  3. 8-K - Current report 171082076
  4. 8-K/A [Amend] - Current report 171041750
  5. 8-K - Current report 171036138

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 2018.
Roxadustat - ANDES
Anaemia
Phase 3 trial initiated 3Q 2017.
Roxadustat
Myelodysplastic syndromes (MDS)
Phase 3 data from China trial released January 30, 2017. NDA to be filed with FDA in 2018. China regulatory filing due 3Q 2017.
Roxadustat
Anemia in chronic kidney disease
Phase 2 trial enrollment commenced January 2016. Continues to enroll as of November 2016.
FG-3019
Duchenne muscular dystrophy
Phase 2 ongoing in Hong Kong. Future development uncertain
FG-3019
Liver fibrosis
Phase 2 data released August 7, 2017 - primary endpoint met.
Pamrevlumab (FG-3019)
Idiopathic pulmonary fibrosis
Phase 2 ongoing. Data due late 2017 or 1Q 2018.
Pamrevlumab (FG-3019)
Pancreatic cancer

Latest News

  1. Spectrum Shares Surge on Data for Lung Cancer Drug -- Biotech Movers
  2. FibroGen Announces Acceptance by China FDA of Roxadustat New Drug Application (NDA) for Treatment of Anemia Associated With Dialysis and Non-Dialysis Chronic Kidney Disease (CKD)
  3. See what the IHS Markit Score report has to say about FibroGen Inc.
  4. ETFs with exposure to FibroGen, Inc. : October 13, 2017
  5. Cramer's lightning round: Let Nike walk these losses off
  6. 3 Under-the-Radar Small Cap Gems
  7. FibroGen Inc (FGEN): How Does It Impact Your Portfolio?
  8. FibroGen, Inc. :FGEN-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017
  9. FibroGen Appoints Gerald Lema to Board of Directors
  10. Why This Cancer Biotech Leads Pack After Hitting Record High
  11. Fibrogen Presents Latest Data From Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at European Respiratory Society (ERS) International Congress 2017
  12. Is There Now An Opportunity In FibroGen Inc (FGEN)?
  13. FibroGen Announces Pamrevlumab Oral and Poster Presentations at European Respiratory Society International Congress 2017
  14. Biotech Movers: Red Hill Jumps After Securing Rights Sell GERD Treatment
  15. FibroGen, Inc. Announces Pricing of Follow-On Offering of Common Stock
  16. FibroGen, Inc. Announces Proposed Follow-On Offering of Common Stock
  17. IHS Markit Score Update: Drop in demand for ETFs holding FibroGen Inc is a negative sign for its shares

SEC Filings

  1. 8-K - Current report 171141793
  2. 8-K - Current report 171092595
  3. 8-K - Current report 171082076
  4. 8-K/A [Amend] - Current report 171041750
  5. 8-K - Current report 171036138
  6. 424B5 - Prospectus [Rule 424(b)(5)] 171036106
  7. 424B5 - Prospectus [Rule 424(b)(5)] 171032260
  8. 8-K - Current report 171026639
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 171011625
  10. 8-K - Current report 171011516